MCIA – ACannabis

Each year ACannabis brings together participants from across the medicinal cannabis ecosystem, including policy makers, governments, global leaders, healthcare professionals, patients and industry participants to share knowledge, exchange ideas and showcase leading edge industry technologies and opportunities.

Please find below exclusive access to four sessions from ACannabis 2022.

Don’t miss ACannabis 2023 on 14 & 15 March. Stay up to date with speaker and event announcements at

In Conversation: Regulatory landscape & opportunities in the EU medicinal cannabis market

ACannabis 2022, Session 3

Martin Lane, Founder, Cannabiz
Nick Pateras Managing Director, Europe Materia

Navigating patient access: panel discussion with allied professions

ACannabis 2022, Session 6

Carol Ireland CEO Epilepsy Action Australia

Dr Jane Chapman, MBBS, FRACGP Holistic Biomedical, Doctor and Owner, Won Wellness. Athena Kolivos, Pharmacist
Chetna Patel, Pharmacist
Dr John Lawson B.Med FRACP PhD. Medical Director Rural, Regional, and Remote Clinical Trial Enabling Program Office for Health and Medical Research. Paediatric neurologist at Sydney Children’s Hospital, Randwick and Associate Senior Lecturer, University of NSW.

How the Australian regulatory environment is evolving and implications for patients and industry

ACannabis 2022, Session 11

Nathan Davis, Chief Operations Officer – Executive Director, MedReleaf Australia

Part 1: Presentations
Adj Prof John Skerritt, Deputy Secretary for Health Products Regulation, Department of Health
Danielle Chifley, Director – Medicinal Cannabis Section, Office of Drug Control, Australian Government Department of Health
Petra Bismire, Director, Experimental Products Section, Therapeutic Goods Administration

Part 2: Panel Discussion
‘Understanding changes to the TGA process for medicinal cannabis applications and implications for prescribers, patients and sponsors’

Clare Barker, General Manager & Global Business Development Executive, Entoura
Elisabetta Faenza, Director, MCIA

The patient access landscape around the globe – how does Australia compare and how can we maximise opportunities?

ACannabis 2022, Session 14

Dr Jaroslav Boublik BSc (Hons), PhD (Med), CEO, LeafCann Research & Advisory and Chief Scientist, LeafCann Group
José Tempero, PharmD MSc, Director, Medical Affairs, Global Tilray